Navigation Links
Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
Date:9/17/2013

INDIANAPOLIS, Sept. 17, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that a total of 31 abstracts will be presented at the 49th European Association for the Study of Diabetes Annual Meeting in Barcelona, September 23-27. In seven presentations, Lilly will share Phase III data for dulaglutide, its investigational GLP-1 receptor agonist, and Phase II data for LY2605541, its investigational novel basal insulin analog.

Seventeen abstracts will be presented by Boehringer Ingelheim on behalf of the Alliance with Lilly.

Lilly will present an additional seven abstracts, including research from its early-stage pipeline. Lilly's pipeline comprises nearly a dozen potential new medicines for the treatment of diabetes and its related conditions, encompassing both large and small molecules, and targeting a variety of mechanisms.

Following are details on some of the presentations from Lilly's late-stage pipeline.

Dulaglutide Data  
Six dulaglutide abstracts will be presented, including efficacy, safety and health outcomes data from the Phase III programme. One of these abstracts will be given as an oral presentation. Details for the presentations are as follows:

  • Tuesday, 24 September 2013, 10:45-12:15 CEST, Oral Presentation
    • Efficacy and safety of dulaglutide vs metformin in type 2 diabetes (AWARD-3) (Santiago Tofe Povedano) [Presentation 4]

  • Tuesday, 24 September 2013, 13:45-14:45 CEST, General Poster Session
    • Dose-finding results in an adaptive trial of dulaglutide combined with metformin in type 2 diabetes (AWARD-5) (Zachary Skrivanek) [Poster No. 1003] 

  • Thursday, 26 September 2013, 13:45-14:45 CEST, General Poster Session
    • Efficacy and safety of dulaglutide versus placebo and exenatide in type 2 diabetes (AWARD-1) (Carol Wysham) [Poster No. 919]
    • Safety and efficacy of dulaglutide vs sitagliptin after 104 weeks in type 2 diabetes (AWARD-5) (Bruno Guerci) [Poster No. 920]
    • Efficacy and safety of dulaglutide vs sitagliptin after 52 weeks in type 2 diabetes (AWARD-5) (Michael Nauck) [Poster No. 921]
    • Patient-reported outcomes with dulaglutide, exenatide, or placebo (AWARD-1) (Kate Van Brunt) [Poster No. 985]

Novel Basal Insulin Analog (LY2605541) Data 
One Phase II abstract will be presented for LY2605541. Details for the presentation are as follows:

  • Thursday, 26 September 2013, 12:30-13:30 CEST, General Poster Session
    • LY2605541 exhibits a flatter glucodynamic profile than insulin glargine at steady state in subjects with type 1 diabetes (Linda Morrow) [Poster No. 1030]

About Diabetes
Approximately 25.8 million Americans1 and an estimated 371 million people2 worldwide have type 1 and type 2 diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases. Diabetes is a chronic disease that occurs when the body either does not properly produce, or use, the hormone insulin.3

About Lilly Diabetes 
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and our continued commitment to providing real solutions — from medicines to support programs and more — to make lives better. For more information, visit www.lillydiabetes.com.

About Eli Lilly and Company  
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers — through medicines and information — for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

P-LLY

This press release contains forward-looking statements about two investigational compounds, dulaglutide and novel basal insulin LY2605541, which are currently in development for the treatment of diabetes. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that dulaglutide and/or novel basal insulin LY2605541 will receive required regulatory approvals or prove to be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

1 Centers for Disease Control. National Diabetes Fact Sheet-2011. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed on: February 22, 2012. 
2 International Diabetes Federation. Diabetes Atlas, 5th Edition: Fact Sheet. 2012. 
3 International Diabetes Federation. Diabetes Atlas, 5th Edition: What is Diabetes? http://www.idf.org/diabetesatlas/5e/what-is-diabetes. Accessed on: February 22, 2012.

Refer to: Candace Johnson (for dulaglutide inquiries), +1-317-755-9143, johnson_candace_a@lilly.com  
Tamara Hull (for novel basal insulin inquiries), +1-317-651-9116, hull_tamara@lilly.com

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
2. Dr. Marschall S. Runge Elected to Lilly Board of Directors
3. Lilly Reports Second-Quarter 2013 Results
4. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
5. Lilly Disappointed in Draft Medicare Coverage Decision for Beta-Amyloid Imaging Agents
6. The Zacks Analyst Blog Highlights: Walgreens, Express Scripts Holding, Haemonetics, ResMed and Eli Lilly
7. Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests
8. Lilly Declares Third-Quarter 2013 Dividend
9. Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimers Disease
10. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
11. Lilly Statement on Indiana Biosciences Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Oct. 2, 2017 The Rebound mobile app is ... to reverse the tide of prescription drug addiction. The app ... medicine intake and stepping down their dosage in a safe, ... in December 2017; the first 100,000 people to sign up ... http://www.rebound-solution.com/ ...
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder ... of ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership ... rules. It also provides a forum to network with elder law attorneys nationwide,” said ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
Breaking Medicine News(10 mins):